FDA Can’t Find Efficacy For BioMarin’s Drisapersen
This article was originally published in The Pink Sheet Daily
On verge of advisory committee meeting, FDA says development program was exemplary, but is disappointed data are inconclusive.
You may also be interested in...
The Greatest FDA Advisory Committees Of All Time Part IV: Neurology Lays Claim To The Crown
We look back at another of the greatest FDA advisory committees of the last 20 years. This time: the nearly 12-hour meeting in 2016 on Sarepta’s eteplirsen for Duchenne muscular dystrophy.
Benefit-Risk Frameworks May Be Coming To US FDA Advisory Committees
Structured assessments, which are currently publicly available only for approved products, could help frame questions for panel discussion of specific drugs under review; FDA also exploring ways to make completed frameworks more readily accessible.
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.